HCAT Q3 2026 deep dive: client retention and cost alignment take center stage

Health Catalyst (HCAT) reported Q3 2026 revenue of $56.28M, beating estimates by 1.5%, with adjusted EPS of -$0.03, also beating estimates. The company reconfirmed full-year revenue guidance of $247.5M and EBITDA guidance of $18.25M. CEO Simeon Kohl highlighted client retention as a priority, while the company is realigning costs and simplifying its product portfolio. HCAT is now debt-free with $79M in cash, aiming to improve margins and service delivery.

Original reporting
Published Nov 9, 2026, 3:57 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 4:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HCAT Q3 2026 deep dive: client retention and cost alignment take center stage — source image
Decision brief

The 30-second read

$HCATBearishMed
01

Why it matters

The earnings miss and lowered guidance suggest near‑term downside, but strategic cost cuts and a debt‑free balance sheet may support a longer‑term recovery.

02

Market read

Micro‑cap health‑tech stock with immediate earnings‑driven risk; sector peers may be impacted by similar retention challenges.

03

What to watch

Potential upside from upcoming product simplification and deeper client engagements not yet reflected in the price.

Relevance 6/10Novelty 7/10Timing: post‑market release today

Background

Health Catalyst (HCAT) reported Q3 2026 results with a 26% YoY revenue decline and highlighted client churn as a key issue.

Company-level read

Ticker impact

$HCATBearishHigh confidence
Context

Q3 2026 earnings release with revenue miss, guidance below estimates and client churn highlighted.

Expected impact

likely downside as market prices in revenue miss and churn concerns

Evidence & confidence

Revenue fell 26% YoY and missed estimates; guidance for full-year EBITDA is below consensus, indicating near‑term earnings pressure.

Market effects

Highlights challenges in the health‑tech sector around client retention and cost structure.

U.S. micro‑cap health‑tech stocks may see short‑term pressure.

Limited to niche health‑data analytics space.

Counterpoint

Cost realignment and debt‑free balance sheet could enable a turnaround, offering a buying opportunity at lower valuations.

Key entities

  • Simeon Kohl

    CEO who emphasized client retention and cost realignment.

Related articles

$HCATMed

Health Catalyst Reports Third Quarter 2026 Results

Health Catalyst, Inc. (HCAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Health Catalyst Reports Third Quarter 2026 Results SALT LAKE CITY, UT, November 5, 2026 — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported finan

$HCATMedAI 8/10

Health Catalyst (HCAT) Q2 2026 Earnings Call Transcript

Health Catalyst (HCAT) reported Q2 2026 revenue of $70.5M, down 13% from $80.7M a year earlier. Technology revenue fell to $48.8M and professional services to $21.7M. The company completed the Vitalware divestiture for $147M cash and repaid about $160M of debt. FY2026 guidance: revenue $246M-$249M and adjusted EBITDA $18M-$18.5M.

$HCATHighAI 9/10

Why Health Catalyst (HCAT) Shares Are Trading Lower Today

Health Catalyst (NASDAQ: HCAT) shares fell 23.1% after the company issued a weak Q3 revenue forecast and cut its full-year outlook. It expects Q3 revenue of $55.5 million versus $70.49 million in Q2, and reduced 2026 revenue guidance to $247.5 million at the midpoint. Q2 revenue met expectations, but the outlook pressured the stock.